This content requires an NEJM.org account. Create a free account now. Already have an account? Sign in .

Quick Take Free Preview

Olokizumab for Rheumatoid Arthritis

Continue to access content

Select an option below:

This content requires an account.

Create Account

Already have an account?

Sign In

Second-line therapies for rheumatoid arthritis include drugs targeting the interleukin-6 receptor. Olokizumab, an antibody that binds directly to interleukin-6, might offer another treatment option. New research findings are summarized in a short video.

This content requires an NEJM.org account.

Create Account